Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

GlobeNewswire June 8, 2021

AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire June 7, 2021

UPDATE - FMW Media, Inc.'s "New to The Street" TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET

GlobeNewswire June 4, 2021

FMW Media, Inc.'s "New to The Street" TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET

GlobeNewswire June 4, 2021

AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

GlobeNewswire May 19, 2021

FMW Media, Inc.'s "New to The Street" TV Announces 8 Interviews Being Broadcast on NEWSMAX TV, Sunday, May 16, 2021, Hour Slot 10-11AM ET.

GlobeNewswire May 14, 2021

FMW Media's "New To The Street" Syndicated TV Show Features AzurRx BioPharma, Inc.

GlobeNewswire May 14, 2021

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire May 13, 2021

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

GlobeNewswire May 12, 2021

AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)

GlobeNewswire May 11, 2021

AzurRx BioPharma to Present at Investor Summit Group's Q2 Virtual Investor Summit (May 17)

GlobeNewswire May 11, 2021

AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit

Newsfile May 11, 2021

CEO Presenting on the Emerging Growth Conference on May 12. Register here

GlobeNewswire May 10, 2021

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

GlobeNewswire April 13, 2021

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire April 6, 2021

AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

GlobeNewswire March 31, 2021

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

GlobeNewswire March 31, 2021

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire March 22, 2021

AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

GlobeNewswire March 16, 2021

AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)

GlobeNewswire March 10, 2021